Royalty Pharma/$RPRX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Royalty Pharma

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Ticker

$RPRX
Primary listing

Industry

Pharmaceuticals

Employees

-

Royalty Pharma Metrics

BasicAdvanced
$15B
14.91
$2.45
0.48
$0.86
2.41%

What the Analysts think about Royalty Pharma

Analyst ratings (Buy, Hold, Sell) for Royalty Pharma stock.

Bulls say / Bears say

Royalty Pharma's recent $2 billion funding agreement with Revolution Medicines, including a $1.25 billion synthetic royalty on daraxonrasib and a $750 million secured loan, positions the company to benefit from potential future revenues of this promising therapy. (royaltypharma.com)
The acquisition of its external manager, RP Management, is expected to generate significant cash savings exceeding $100 million in 2026 and $175 million in 2030, enhancing shareholder value. (globenewswire.com)
Royalty Pharma's strong financial performance in Q3 2024, marked by a 15% growth in both Portfolio and Royalty Receipts totaling $735 million, reflects its robust business model and potential for sustained growth. (tipranks.com)
Royalty Pharma's Q4 2024 revenue of $594 million missed analyst estimates of $605.4 million, indicating potential challenges in meeting market expectations. (stockstory.com)
The company's operating margin declined to 60.9% in Q4 2024 from 103% in the same quarter the previous year, suggesting increased operational costs or reduced efficiency. (stockstory.com)
Despite a consensus 'Buy' rating, Citigroup reduced its target price for Royalty Pharma from $60.00 to $40.00, reflecting tempered expectations for the company's stock performance. (techdows.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.

Royalty Pharma Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Royalty Pharma Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $RPRX

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

Aug15
Royalty Pharma
Dividend·Ex-dividend
Sept10
Royalty Pharma
Dividend·Payment
$0.22Per share
FAQs